CardioKinetix, a developer of catheter-based treatment methods for heart failure, has announced the first successful completion of heart failure surgery with Parachute ventricular partitioning device, its minimally invasive structural heart device, in Kuala Lumpur, Malaysia.

The Parachute is a catheter based partitioning device deployed within the left ventricle through a small catheter inserted in the femoral artery of patients who have developed ischemic heart failure following a heart attack.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

By partitioning the damaged muscle and isolating the non-functional muscle segment from the functional segment, the Parachute implant decreases the overall volume and restores a more normal geometry and function in the left ventricle.

The Parachute device helps in achieving better patient outcomes as it improves overall cardiac function and quality of life of patients.

“The Parachute device is an innovative new option that has demonstrated promising results in previous studies.”

Institut Jantung Negara (National Heart Institute) in Kuala Lumpur, Malaysia CEO Dr Robaayah Zambahari said the institute is thrilled that the first Parachute procedure in Asia was performed in Kuala Lumpur.

“The Parachute device is an innovative new option that has demonstrated promising results in previous studies,” Dr Zambahari said.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The Parachute device, which received CE Mark in 2011, is currently enrolling in the US pivotal trial, PARACHUTE IV.

CardioKinetix president and CEO Maria Sainz noted the expansion of the Parachute device into Asia is an important achievement for the company.

“Continuing to partner with leading clinicians and heart centres illustrates the promise the Parachute holds to bring a solution for the underserved heart failure patients around the world,” Sainz said.

Approximately six million people are affected with heart failure in the US, leading to 1.1 million hospitalisations annually.

According to GlobalData estimates, left ventricular assist devices market in the US which was $361.6m in 2012 is expected grow at a CAGR of 15.1% to reach $967m by 2019.